Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Numinus Wellness Inc NUMIF


Primary Symbol: T.NUMI

Healthcare
Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and... see more

Recent & Breaking News (TSX:NUMI)

Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024

PR Newswire April 9, 2024

Numinus Wellness Submits Clinical Trial Application

PR Newswire March 20, 2024

Numinus Wellness Provides Corporate Update

PR Newswire March 12, 2024

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

PR Newswire March 8, 2024

Numinus Wellness Inc. Closes $6 Million Bought Deal Public Offering

Canada NewsWire February 16, 2024

Numinus Wellness Inc. Congratulates Lykos Therapeutics on FDA Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD

Canada NewsWire February 14, 2024

Canadian Investment Regulatory Organization Trade Resumption - NUMI

Canada NewsWire February 2, 2024

Canadian Investment Regulatory Organization Trading Halt - NUMI

Canada NewsWire February 1, 2024

Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.

GlobeNewswire February 1, 2024

Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.

PR Newswire February 1, 2024

/C O R R E C T I O N from Source -- Numinus Wellness Inc./

Canada NewsWire February 1, 2024

Numinus Wellness offers turnkey exposure to psychedelic medicine

Trevor Abes  January 29, 2024

Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results

PR Newswire January 15, 2024

Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024

PR Newswire January 2, 2024

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

PR Newswire December 15, 2023

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

PR Newswire December 13, 2023

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

PR Newswire November 29, 2023

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023

PR Newswire November 21, 2023

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

PR Newswire October 3, 2023

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program

PR Newswire September 25, 2023